Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MYODM-FSMP

Financiado

Cerrado

New food for special medical purposes to nutritionally manage Myotonic Dystrophy...

New food for special medical purposes to nutritionally manage Myotonic Dystrophy type 1 Myotonic Dystrophy type 1 (DM1) is the most common and multisystemic neuromuscular rare disease affecting 1 million people worldwide, 100,000 EU citizens, who still have no cure or treatment available. In the light of the ´Leave... ver más

30/06/2021

MYOGEM HEALTH COMP...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

MYOGEM HEALTH COMPANY (cnae 2110).fabricacion de especialidades de farmacia.cnae 2110

TRL 8-9

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-06-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

MYOGEM HEALTH COMPANY

50.00K€ | Lider

FAMA SYSTEMS

496.54K€ | Participante

Proyectos interesantes

DESARROLLO DE COMPLEMENTOS ALIMENTICIOS PARA...

Medical Technol...

Health Informat...

706K€ Cerrado

PID2020-117859RA-I00

Medical Technol...

Data Science

145K€ Cerrado

OPTIMISTIC

Medical Technol...

Data Science

4M€ Cerrado

ENTRY-DM

Medical Technol...

Data Science

Cerrado

BIOIMAGE-NMD

Medical Technol...

Data Science

8M€ Cerrado

MyoPALM

Medical Technol...

Data Science

321K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 23 meses Fecha Inicio: 2019-07-15
Fecha Fin: 2021-06-30

Líder del proyecto

MYOGEM HEALTH COMPANY (cnae 2110).fabricacion de especialidades de farmacia.cnae 2110

TRL 8-9

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Myotonic Dystrophy type 1 (DM1) is the most common and multisystemic neuromuscular rare disease affecting 1 million people worldwide, 100,000 EU citizens, who still have no cure or treatment available. In the light of the ´Leave No-one Behind´ commitment behind Sustainable Development Goals and particularly, the dietary management approach may provide a unique option for rare disease patients through Foods for special medical purposes (FSMP), foods (not drugs) intended for the dietary management of individuals who suffer from certain diseases. The main goal of the present project is to compile in human evidences that MYODM’s food for special medical purposes is a unique approach to improve DM1 patients’ Quality of Life through a pilot clinical trial for foods and supplements sponsored by Myogem and leaded by Dr. Adolfo López de Munain, a worldwide neurologist specialized in DM1. MYOGEM is the current licensee of the patents WO2016075288 A1 and WO2016075285 A1, which disclosed the effects of some methylxanthines on DM1. Owning the Intellectual Property Rights over the present solution is one of the main competitive advantages of MYOGEM. MYOGEM is the first and unique company worldwide who launched a food supplement for a rare disease in May 2017. However, as food supplement MYODM faces the problem that DM1 community, either neurologists and patient associations, claim for in human data in order to broadly prescribe and consume the product. To overcome this barrier, and gain market confidence, MYOGEM aims to perform a Feasibility pilot clinical trial to demonstrate MYODM’s effect on a small cohort of 10-15 DM1 patients in order to commercially upgrade our current product food supplement to food for special medical purpose, from now on referred as MYODM-FSMP, that will reach the market in less than one year after the present project ends. By launching the new MYODM-FSMP product, a 5.5 M€ SOM is expected in 5 years after the project. Two SoE have been awarded.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores